Jazz Pharmaceuticals (JAZZ) Long-Term Debt Repayments (2020 - 2021)
Jazz Pharmaceuticals' quarterly Long-Term Debt Repayments came in at $218.8 million in Q3 2021, up 839.11% year-on-year from $23.3 million in Q3 2020, and up 839.11% quarter-over-quarter from $23.3 million in Q3 2020.
Jazz Pharmaceuticals has reported Long-Term Debt Repayments for 2 years, with the latest figure at $218.8 million in Q3 2021.
- For the quarter ending Q3 2021, Long-Term Debt Repayments rose 839.11% year-over-year to $218.8 million; the trailing twelve-month figure through Dec 2023 stood at $218.8 million (changed 0.0% YoY), and the FY2024 full-year result was $575.0 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q3 2021 stood at $218.8 million, up from $23.3 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $218.8 million in Q3 2021, with the low at $23.3 million in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 218.81 Mn |
| Sep 30, 2021 | 218.81 Mn |
| Sep 30, 2020 | 23.30 Mn |
| Sep 30, 2020 | 23.30 Mn |